Sponge-derived cyclic peptide compound as well as preparation method and application thereof
A systematic method for extracting and identifying cyclopeptide compounds from deep-sea sponges using chromatography and mass spectrometry-guided separation addresses inefficiencies in existing technologies, enabling the discovery of potent anti-tumor and antioxidant peptides.
Patent Information
- Application Number
- CN202411010864.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-12-03
AI Technical Summary
Existing methods for identifying and extracting bioactive cyclic peptides from deep-sea sponges are inefficient and lack a systematic approach for rapid identification and purification, limiting the discovery and development of novel anti-tumor and antioxidant drugs.
A method involving the extraction of cyclopeptide compounds from brown flat sponges using percolation with organic solvents, followed by chromatography and mass spectrometry-guided separation, coupled with molecular network analysis to identify and isolate specific cyclic peptides, utilizing bioinformatics tools for rapid decomposition and visualization.
The method enables the rapid identification and isolation of novel cyclic peptides with potent anti-tumor and antioxidant activities, providing new lead compounds for drug development and a scientific basis for utilizing marine resources.
Smart Images

Figure CN119060141A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a sponge-derived cyclic peptide compound and a preparation method and application thereof. Background Art
[0002] Sponges are an important source of marine active cyclic peptides, and the extracts of deep-sea sponges often have important biopharmaceutical value. Deep-sea sponges accumulate a lot of organic components through the regulation of the internal environment. These chemicals often have application value in many aspects such as medicine, agriculture, environmental protection, and new materials. According to current research, the bioactive components of deep-sea sponges are considered to have constituted a very broad and diverse treasure trove of biological resources. Since the 1990s, natural cyclic peptides from sponges have exploded, and sponges have once become the largest "reservoir" of marine active cyclic peptides. Among them, Phakellia and Axinella sponges, which are rich in cyclic peptides, grow rapidly and are easy to collect. Novel cyclic peptide compounds continue to be discovered, and most of them contain uncommon amino acids. As drug molecules, cyclic peptide compounds have a wide range of biological activities such as anti-cancer, antibacterial, and antioxidant. Therefore, research on cyclic peptide drugs has received more and more attention.
[0003] With the development of bioinformatics, the integration of bioinformatics tools and analytical chemistry methods, especially mass spectrometry (MS), into the field of natural products has greatly promoted the discovery speed of marine natural products. In this context, the molecular network (MN) technology has emerged and played an important role in the structural association analysis of natural products and the prediction of molecular decomposition. It uses the powerful computing power of computers to effectively organize and visualize the secondary mass spectrometry data sets of complex natural extracts, and automatically associates them with the Global Natural Products Social Molecular Networking (GNPS) database to form an intuitive and vivid molecular network diagram. Through this visual "structural group" analysis, the "rapid decomposition" of natural products can be achieved. Summary of the invention
[0004] The present invention is based on the above research, using brown flat sponge as raw material, extracting cyclopeptide compounds from it, and using bioinformatics tools and analytical chemistry methods to identify and screen the extracted cyclopeptide compounds. Based on this, the first purpose of the present invention is to provide a sponge-derived cyclopeptide compound; the second purpose is to provide a method for preparing the sponge-derived cyclopeptide compound; the third purpose is to provide the use of the sponge-derived cyclopeptide compound in the preparation of anti-tumor and antioxidant drugs.
[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0006] In a first aspect, the present invention provides a sponge-derived cyclic peptide compound, the structural formula of which is shown in any one of Formulas 1 to 5 below:
[0007]
[0008] In a second aspect, the present invention provides a method for preparing the above-mentioned sponge-derived cyclic peptide compounds, comprising the following steps:
[0009] A. Extraction
[0010] The sponge is crushed and extracted by percolation with an organic solvent for multiple times, and the extracts are combined and concentrated under reduced pressure to obtain an extract; preferably, the sponge is selected from brown flat sponge; the brown flat sponge is crushed and extracted by percolation with 95% ethanol for five times; the mass volume ratio between the sponge and the ethanol solution is 10-11:300.
[0011] B. Extraction and separation
[0012] The extract is dispersed in water and extracted with an equal volume of ethyl acetate for 3 to 5 times (preferably 3 times); the ethyl acetate layers are combined and concentrated to obtain an extract which is suspended in 80 to 90% (preferably 85 to 90%) methanol water and extracted with an equal volume of petroleum ether for 3 to 5 times to remove impurities; the 80 to 90% (preferably 85 to 90%) methanol water layer is diluted to 50 to 60% methanol water, extracted with an equal volume of dichloromethane for 3 to 5 times (preferably 3 times); the extracts are combined and concentrated under reduced pressure to obtain a dichloromethane extraction portion.
[0013] C. Separation and enrichment
[0014] The dichloromethane extraction portion in step B is subjected to Sephadex LH-20 gel column chromatography, eluted with 50% CH2Cl2-CH3OH eluent, and mass spectrometry tracking is used to enrich the high molecular weight compounds; then ODS medium pressure column chromatography is used for separation, CH3OH / H2O gradient elution (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, elution for 450 minutes), and mass spectrometry tracking and positioning analysis is used to obtain a fine fraction containing high molecular weight cyclic peptide compounds.
[0015] D. Screening of target compounds
[0016] The fine fraction in step C was subjected to secondary mass spectrometry data collection, and the collected mass spectrometry data were uploaded to the GNPS database for molecular network analysis; the known molecule phakefustatin A (PF-A) was used as a probe molecule to fish and track the cyclic peptide molecules in the fraction to obtain molecular nodes that were correlated with phakefustatin A; two molecular nodes with a large correlation with phakefustatin A were found in the formed molecular network diagram, with molecular weights of m / z 912.423 and 896.475 [M+H], respectively. + ; Three other new cyclic peptide nodes were found in another molecular cluster, with molecular weights of m / z 828.503, 788.426 and 855.401 [M+H] + .
[0017] E. Mass spectrometry-guided separation
[0018] Based on the obtained fragment ion and chromatographic retention information, the fine fractions are separated by mass spectrometry-guided semi-preparative high performance liquid chromatography to obtain the target compounds of formulas 1 to 5.
[0019] The separation conditions of mass spectrometry-guided semi-preparative HPLC were as follows: 35-45% acetonitrile-water, flow rate 6.0 mL / min, and detection of molecular ions 912.423, 896.475, and 855.401 in positive ion mode; 25-35% acetonitrile-water, flow rate 6.0 mL / min, and detection of molecular ions 828.503 and 788.426 in positive ion mode.
[0020] The third aspect of the present invention provides the medical uses of the above five sponge-derived cyclopeptide compounds. The results of in vitro cell experiments showed that compound 1 had an inhibitory effect on six tumor cells (MCF-7, HeLa, PC9, HepG2, A2780 and NB4) and was not toxic to normal cells; compounds 2 to 5 could significantly increase the expression of antioxidant enzymes HO-1, NQO1 and SOD2 and antioxidant-related nuclear factor Nrf2, and are potential antioxidant drugs.
[0021] Therefore, the present invention provides the use of a sponge-derived cyclopeptide compound in the preparation of an anti-tumor drug, and the structure of the sponge-derived cyclopeptide compound is as follows:
[0022]
[0023] Correspondingly, an anti-tumor drug composition with the above structural formula as an active ingredient is provided.
[0024] Preferably, the tumor includes breast cancer, cervical cancer, lung cancer, liver cancer, ovarian cancer, and leukemia.
[0025] In addition, the present invention also provides the use of a sponge-derived cyclopeptide compound in the preparation of an antioxidant drug, wherein the structure of the sponge-derived cyclopeptide compound is selected from any one of the following:
[0026]
[0027]
[0028] Correspondingly, an antioxidant pharmaceutical composition having any one or more of the four structural formulas as active ingredients is also provided.
[0029] Beneficial technical effects of the present invention:
[0030] The present invention provides a mass spectrometry rapid positioning method for selectively identifying cyclic peptide compounds from complex extracts. Using phakefustatin A (PF-A) as a probe, molecular network visualization analysis of the secondary mass spectrometry data of the extract was performed, from which the parent ions were found to be m / z 912.423, 896.475, 828.503, 788.426 and 855.401 [M+H] + The new cyclic peptide node was identified and separated by mass spectrometry-guided semi-preparative HPLC based on its fragment ion and chromatographic retention information to obtain 5 new cyclic peptide compounds.
[0031] The peptide compounds of the present invention show strong inhibitory activity against MCF-7 and PC9 tumor cells, wherein the IC50 values of compound 1 against these two tumor cells are 6.8 and 9.1 μM, respectively, which is equivalent to the activity of the positive drug cisplatin, and has low toxicity to normal cells HaCaT, with IC50>40 μM. The peptide compounds of the present invention have a protective effect on the oxidative damage of HaCaT cells induced by hydrogen peroxide, and significantly improve the viability of oxidatively damaged cells. The mechanism of action study found that compounds 2-5 can significantly increase the expression of antioxidant enzymes HO-1, NQO1 and SOD2 and antioxidant-related nuclear factor Nrf2. Therefore, the compounds of the present invention can be used to prepare anti-tumor and antioxidant drugs.
[0032] The sponge cyclic peptide compound provided by the invention has a simple preparation method and significant anti-tumor and antioxidant activities. The invention provides a new lead compound for the research and development of new anti-tumor and antioxidant drugs, provides a new method for the rapid identification and directional tracking of trace cyclic peptide active ingredients, and provides a scientific basis for the development and utilization of my country's marine medicinal resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is the discovery process of sponge ring peptide compounds 1-5 based on molecular networks.
[0034] Figure 2This is a schematic diagram of 2D NMR correlation and MS / MS fragmentation detection of sponge cyclic peptide compound 1, where A, key 2D NMR correlation signal analysis; B, structural fragmentation schematic diagram; C, ESI-QTOF-MS / MS mass spectrometry analysis.
[0035] Figure 3 It is a schematic diagram of 2D NMR related to sponge ring peptide compounds 2-5, wherein A, 2D NMR analysis of compound 2; B, 2D NMR analysis of compound 3; C, 2D NMR analysis of compound 4; D, 2D NMR analysis of compound 5.
[0036] Figure 4 This is the LC-MS detection diagram of the advanced Marfey's analysis of sponge cyclic peptide compound 1, where a, Pro; b, Val; c, Arg; d, Phe; e, DiOia.
[0037] Figure 5 This is a dose-effect curve of sponge cyclic peptide compound 1 on MCF-7 and PC9 tumor cells.
[0038] Figure 6 This is a schematic diagram of the antioxidant activity of sponge cyclic peptide compound 2-5, wherein A, the effect of compound 2-5 on the viability of oxidatively damaged HaCaT cells; B, the effect of compound 2-5 on the expression of antioxidant-related proteins; C, statistical analysis of the effect of compound 2-5 on the expression of antioxidant-related proteins. DETAILED DESCRIPTION
[0039] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.
[0040] Example 1 Extraction of sponge ring peptide compounds 1-5
[0041] Using brown flat sea sponge (Phakelliafusca) as raw material and the known molecule phakefustatin A as probe molecule, the MS / MS mass spectrometry data of the collected extracts were uploaded to the GNPS database for molecular network analysis, and the cyclic peptide molecules in the fractions were tracked. Figure 1 As shown in the molecular network diagram, two molecular nodes with a high correlation with PF-A were found, with molecular weights of m / z 912.423 and 896.475 [M+H], respectively. + , and three other new cyclic peptide nodes were found in another molecular cluster, with molecular weights of m / z 828.503, 788.426 and 855.401 [M+H] +Based on the information of its fragment ions and chromatographic retention behavior, it was separated by mass spectrometry-guided preparative liquid phase to obtain 5 new cyclic peptide compounds, namely sponge cyclic peptide compounds 1-5.
[0042] The specific steps of extracting sponge cyclic peptide compounds 1-5 from sponges are as follows:
[0043] The first step is extraction: a brown flat sponge (Phakelliafusca) (dry weight 2.2 kg) (collected from the waters near Yongle Island in the South China Sea) is crushed and extracted five times with 60 L of 95% ethanol by percolation. The combined extracts are concentrated under reduced pressure, the ethanol is recovered, and the extract is concentrated to obtain an extract.
[0044] The second step is extraction and separation: the extract is extracted three times with an equal volume of ethyl acetate, and the ethyl acetate layers are combined and concentrated to obtain an ethyl acetate layer extract (106.8 g); the ethyl acetate layer extract is suspended in 90% methanol water, extracted three times with an equal volume of petroleum ether, and the extracts are combined and concentrated under reduced pressure to obtain a petroleum ether portion (47.5 g); the 90% methanol water layer is diluted to 60% methanol water, extracted three times with an equal volume of dichloromethane, and the extracts are combined and concentrated under reduced pressure to obtain a dichloromethane portion (21.0 g).
[0045] The third step is separation and enrichment: 21.0 g of the dichloromethane extraction part is chromatographed on a Sephadex LH-20 gel column, eluted with 50% CH2Cl2-MeOH eluent, and the high molecular weight compounds are enriched to obtain 8.3 g. ODS medium pressure column chromatography is used for separation, eluted with MeOH / H2O gradient (10%-100%, 450 min), and mass spectrometry tracking and positioning analysis is used to obtain a fine fraction containing high molecular weight cyclopeptide compounds.
[0046] The fourth step is to screen the target compounds: collect the secondary mass spectrometry data of the above-mentioned fine fractions, upload the collected MS / MS mass spectrometry data to the GNPS database for molecular network analysis, and use the reported known molecule phakefustatin A (PF-A) as a probe molecule to track the cyclic peptide molecules in the fraction. Finally, two molecular nodes with a high correlation with PF-A were found in the formed molecular network diagram, with molecular weights of m / z 912.423 and 896.475 [M+H] respectively. + In addition, three other new cyclic peptide nodes were found in another molecular cluster, with molecular weights of m / z 828.503, 788.426 and 855.401 [M+H] + Screening principle and the sponge ring peptide compounds 1-5 obtained by screening Figure 1 shown.
[0047] The fifth step is mass spectrometry-guided separation: based on the fragment ion information and chromatographic retention behavior, the above-mentioned fine fractions are separated by mass spectrometry-guided semi-preparative high performance liquid chromatography (35-45% acetonitrile-water, flow rate 6.0 mL / min, molecular ions 912.423, 896.475 and 855.401 are detected in positive ion mode; 25-35% acetonitrile-water, flow rate 6.0 mL / min, molecular ions 828.503 and 788.426 are detected in positive ion mode).
[0048] The structures of compounds 1 to 5 are shown below:
[0049]
[0050] The physicochemical properties and nuclear magnetic resonance data of the sponge cyclic peptide compounds 1-5 prepared by the above steps are as follows:
[0051] Compound 1: light yellow powder; [α] 25 D -60.7(c 0.10,MeOH);IR(ATR)ν max 3283,2925,1621,1528,1446,1345,1245,1206,1104,751,701cm -1 ; HRMS (ESI) m / z: [M+H] + Calcd for C 46 H 62 N 11 O9912.4732, found 912.4728.
[0052] Compound 2: light yellow powder; [α] 25 D -87.0(c 0.10,MeOH);IR(ATR)ν max 3270,2927,1713,1621,1528,1443,1344,1240,1186,750,701cm -1 ; HRMS (ESI) m / z: [M+H] + Calcd for C 46 H 62 N 11 O8896.4783, found 896.4799.
[0053] Compound 3: white amorphous powder; [α] 25 D -28.0(c 0.10,MeOH);IR(ATR)ν max3298,2963,2926,1654,1620,1515,1450,1382,1015,824cm -1 ; HRMS (ESI) m / z: [M+H] + Calculate for C 39 H 58 N9O9S,828.4078,found 828.4075.
[0054] Compound 4: white amorphous powder; [α] 25 D -32.4(c 0.10,MeOH); IR(ATR)ν max 3297,2958,1633,1528,1440,1352,1187,1089,867,744,701cm -1 ; HRMS (ESI) m / z: [M+H] + Calculate for C 41 H 58 N9O7,788.4459,found 788.4467.
[0055] Compound 5: white amorphous powder; [α] 25 D -38.7(c 0.10,MeOH);IR(ATR)ν max 3307,2954,1635,1525,1440,1329,1245,1189,754,702cm -1 ; HRMS (ESI) m / z: [M+H] + Calculate for C 45 H 59 N8O9,855.4405,found 855.4407.
[0056] The NMR spectra data of sponge ring peptide compounds 1-5 are shown in Tables 1 and 2.
[0057] Table 1: NMR spectra of compounds 1 and 2 ( 1 H 600MHz, 13 C 150MHz)
[0058]
[0059]
[0060]
[0061] a:DMSO-d6; b :Pyridine-d5; c :overlapped signals.
[0062] Compounds 1 and 2 have similar planar structures. Through careful analysis of 2D NMR (TOCSY, COSY and HMBC) spectra, it can be determined that the 7 amino acid residues constituting compound 1 include one phenylalanine, one valine, one arginine, one dioxindolealanine and three prolines; the 7 amino acid residues constituting compound 2 include one phenylalanine, one valine, one arginine, one oxidized indolealanine and three prolines.
[0063] The connection order of the seven amino acid residues in compounds 1 and 2 was determined by analyzing HMBC and ROESY related signals and ESI-MS / MS. HMBC related signals Arg-NH / Dioia-CO, Dioia-NH / Phe-CO, Phe-NH / Pro 1 -CO and Val-NH / Pro 3 -CO, the structural fragment Pro 1 -Phe-Dioia-Arg and Pro 3 -Val. Combined with ROESY related signal Arg-Hα / Pro 2 -Hδ、Pro 2 -Hα / Pro 3 -Hα and Val-Hα / Pro 1 -Hδ, the structure of compound 1 was determined to be cyclo-(Pro 1 -Phe-Dioia-Arg-Pro 2 -Pro 3 -Val). ESI-QTOF-MS / MS mass spectrometry revealed the presence of a series of "by" fragment ion pairs (m / z 756.3751 / 157.1080, 538.3030 / 375.1813, 391.2350 / 522.2483, 294.1826 / 619.3007195.1133 / 718.3695 and 98.0611 / 815.4222) corresponding to the loss of Arg, Dioia, Phe, Pro, Val and Pro in sequence, which confirmed the NMR structural analysis results of the cyclic peptide (e.g. Figure 2 As shown, Figure 2 Schematic diagram of 2D NMR correlation and MS / MS fragmentation detection of sponge cyclic peptide compound 1). Similarly, the structure of compound 2 was determined to be cyclo-(Pro 1 -Phe-Oia-Arg-Pro 2 -Pro3 -Val).
[0064] Table 2: NMR spectra of compounds 3-4 ( 1 H 600MHz, 13 C 150MHz,DMSO-d6.)
[0065]
[0066]
[0067]
[0068] a :overlapped signals.
[0069] By carefully analyzing the 2D NMR (TOCSY, COSY, HMBC and ROESY) spectra of compounds 2 to 5 ( Figure 3 ), combined with ESI-MS / MS verification, the structure of compound 3 was determined to be cyclo-(Pro-Ile 1 -Tyr-MetO-His-Gly-Ile 2 ); the structure of compound 4 is cyclo-(Pro 1 -Phe-Leu-Pro 2 -Pro 3 -His-Val); the structure of compound 5 is cyclo-(Pro 1 -Glu-Et-Leu-Trp-Pro 2 -Phe-Gly).
[0070] The absolute configuration of each amino acid residue was determined by the advanced Marfey's method. The compound (0.1 mg) was hydrolyzed with 6N hydrochloric acid at 110°C for 6 h and then derivatized with L-FDLA. The corresponding L-amino acid standard was derivatized with D / L-FDLA. The obtained derivatives were analyzed by UPLC-ESI-QTOF-MS. The absolute configuration was determined by comparing the retention time of each amino acid derivative in the sample with that of the standard derivative. Figure 4 The absolute configuration of each amino acid residue of the compound 1 of the present invention is shown. The retention times of the amino acid standard derivatives of compounds 1-5 are shown in Table 3. The analysis results show that all the amino acid residues of the cyclic peptide compounds are in L-configuration.
[0071] Table 3: Advanced Marfey's mass spectrometry analysis results of compounds 1-5
[0072]
[0073] Example 2 In vitro activity test
[0074] 2-1 Cytotoxic activity assay
[0075] The cytotoxic activity of the test compound against six tumor cell lines (MCF-7, HeLa, PC9, HepG2, A2780 and NB4) and one normal cell line (HaCaT). The samples were dissolved in DMSO and stored at low temperature. The concentration of DMSO in the final system was controlled within the range that did not affect the detection activity. The dilution ratio was 1-100 μg / mL. Cells in the logarithmic growth phase were taken and made into a single cell suspension of 1×10 6 / mL, add the suspension to a 96-well plate, add 100μL to each well. After culturing in a 5% CO2, 37°C incubator for 24 hours, add the test drugs of various concentrations to make the final concentrations 0.03, 0.10, 0.30, 1.0, 3.0, and 10μM, respectively. Each sample has 3 replicate wells. The negative control is an equal volume of culture medium and the corresponding DMSO concentration as the solvent control to eliminate the effect of DMSO on cell growth. The positive control drug is cisplatin. After culturing in a 5% CO2, 37°C incubator for 48 hours, add 10μL of CCK8 solution to each well. After continuing to culture for 4 hours, measure the absorbance (OD value) of each well at 450nm. The inhibition percentage is determined by using the linear regression method, and then the IC 50 In general, each sample was tested in duplicate (n=3), and the results were expressed as standard deviation (SD). IC50% effective inhibitory concentration of compound 1 on different cells 50 The values are shown in Table 4.
[0076] Table 4: Cytotoxic activity of compound 1
[0077]
[0078] Figure 5 The dose-effect curve of sponge ring peptide compound 1 on MCF-7 and PC9 tumor cells is shown. As can be seen from the figure, the peptide compound 1 of the present invention shows strong inhibitory activity on MCF-7 and PC9 tumor cells, IC 50 The values were 6.8 and 9.1 μM, respectively, which were comparable to the activity of the positive drug cisplatin and had low toxicity to normal cells HaCaT. 50 >40μM. The compound 1 of the present invention is a potential anti-tumor drug and provides a new lead compound for the development of new anti-tumor drugs.
[0079] 2-2 Antioxidant Experiment
[0080] Test compound toxicity to HaCaT cells damaged by hydrogen peroxide. Samples were dissolved in DMSO and stored at low temperature. The concentration of DMSO in the final system was controlled within the range that did not affect the detection activity. The dilution ratio was 1-100 μg / mL. Cells in logarithmic growth phase were taken and made into single cell suspension of 1×10 6 / mL, add the suspension to a 96-well plate, add 100μL to each well. After culturing in a 5% CO2, 37°C incubator for 24 hours, add various concentrations of the test drugs to make the final concentrations of 2.5, 5 and 10μM, respectively. Each sample has 3 replicate wells. The negative control is an equal volume of culture medium and the corresponding DMSO concentration as the solvent control to eliminate the effect of DMSO on cell growth. The positive control drug is vitamin E. After culturing in a 5% CO2, 37°C incubator for 24 hours, add H2O2 with a final concentration of 400μM to treat the cells for 2 hours, and determine the cell survival rate by the CTG method. Add 100μL of CTG reagent to each well, incubate for 10 minutes, and then determine the ATP content by a multifunctional microplate reader. The results are as follows Figure 6 As shown, the peptide compounds 2-5 of the present invention have a protective effect on the oxidative damage of HaCaT cells induced by hydrogen peroxide ( Figure 6 A), significantly improving the viability of oxidatively damaged cells. Western blot analysis showed that compounds 2-5 could significantly increase the expression of antioxidant enzymes HO-1, NQO1 and SOD2 and antioxidant-related nuclear factor Nrf2 ( Figure 6 B, 6C). Compounds 2-5 of the present invention are potential antioxidant drugs, and provide new lead compounds for the development of new antioxidant drugs.
[0081] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment, it is not used to limit the present invention. Any technician familiar with this patent can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.
Claims
1. A sponge-derived cyclic peptide compound, characterized in that: The structural formula is shown in any one of the following formulas 1 to 5:
2. The method for preparing the sponge-derived cyclic peptide compound according to claim 1, characterized in that: The steps include: A. Extraction After the sponge is crushed, it is extracted by percolation with an organic solvent for multiple times, and the extracts are combined and concentrated under reduced pressure to obtain an extract concentrate; B. Extraction and separation The extract is dispersed in water and extracted with an equal volume of ethyl acetate for 3 to 5 times. The ethyl acetate layers are combined and concentrated to obtain an extract which is suspended in 80 to 90% methanol water and extracted with an equal volume of petroleum ether for 3 to 5 times to remove impurities. The 80 to 90% methanol water layer is diluted to 50 to 60% methanol water, extracted with an equal volume of dichloromethane for 3 to 5 times, and the extracts are combined and concentrated under reduced pressure to obtain a dichloromethane extraction part. C. Separation and enrichment The dichloromethane extraction part in step B is subjected to gel column chromatography, eluted with 50% CH2Cl2-CH3OH eluent, and the large molecular weight compounds are enriched by mass spectrometry tracking; then ODS medium pressure column chromatography is used for separation, CH3OH / H2O gradient elution is used, and mass spectrometry tracking and positioning analysis is used to obtain a fine fraction containing large molecular weight cyclopeptide compounds; D. Screening of target compounds Perform secondary mass spectrometry data collection on the fine fraction in step C, and upload the collected mass spectrometry data to the GNPS database for molecular network analysis; use the known molecule phakefustatinA as a probe molecule to fish and track the cyclic peptide molecules in the fraction to obtain molecular nodes that are correlated with phakefustatinA; E. Mass spectrometry-guided separation Based on the obtained fragment ion and chromatographic retention information, the fine fractions are separated by mass spectrometry-guided semi-preparative high performance liquid chromatography to obtain the target compounds of formulas 1 to 5.
3. The method for preparing the sponge-derived cyclic peptide compound according to claim 2, characterized in that: in, In step A, the sponge is selected from brown flat sponge; the brown flat sponge is crushed and then extracted five times by percolation with 95% ethanol; the mass volume ratio between the sponge and the ethanol solution is 10-11:
300.
4. The method for preparing the sponge-derived cyclic peptide compound according to claim 2, characterized in that: in, In step B, the extraction times of ethyl acetate, petroleum ether and dichloromethane are all 3 times, and the concentration of methanol water is 85-90%; In step C, column chromatography is performed using a Sephadex LH-20 gel column; When performing ODS medium-pressure column chromatography separation, use CH3OH / H2O at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100% respectively for gradient elution for 450 min.
5. The method for preparing the sponge-derived cyclic peptide compound according to claim 2, characterized in that: in, In step D, two molecular nodes with a high correlation with phakefustatin A were found in the molecular network diagram, with molecular weights of m / z 912.423 and 896.475 [M+H], respectively. + ; Three other new cyclic peptide nodes were found in another molecular cluster, with molecular weights of m / z 828.503, 788.426 and 855.401 [M+H] + ; In step E, the separation conditions of mass spectrometry-guided semi-preparative HPLC are as follows: 35-45% acetonitrile-water, flow rate 6.0 mL / min, and detection of molecular ions 912.423, 896.475, and 855.401 in positive ion mode; 25-35% acetonitrile-water, flow rate 6.0 mL / min, and detection of molecular ions 828.503 and 788.426 in positive ion mode.
6. Use of sponge-derived cyclic peptide compounds in the preparation of anti-tumor drugs, characterized in that: The structure of the sponge-derived cyclic peptide compound is as follows:
7. An anti-tumor drug composition, characterized in that: The invention comprises an active component and a pharmaceutically acceptable excipient, wherein the active component comprises a sponge-derived cyclic peptide compound having the following structure:
8. The antitumor pharmaceutical composition according to claim 7, characterized in that: The tumors include breast cancer, cervical cancer, lung cancer, liver cancer, ovarian cancer, and leukemia.
9. Use of sponge-derived cyclopeptide compounds in the preparation of antioxidant drugs, characterized in that: The structure of the sponge-derived cyclic peptide compound is selected from any one of the following:
10. An antioxidant pharmaceutical composition, characterized in that: The invention comprises an active component and a pharmaceutically acceptable excipient, wherein the active component comprises a sponge-derived cyclic peptide compound having any one or more of the following structures:
